ABOS Acumen Pharmaceuticals
- 3.490
- +0.010+0.29%
- 3.600
- +0.110+3.15%
Acumen Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Acumen Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer's Treatment Development and Attractive Valuation
BTIG Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)
Deutsche Bank Initiates Coverage On Acumen Pharmaceuticals With Buy Rating, Announces Price Target of $8
Acumen Pharmaceuticals Analyst Ratings
Promising Biomarker Data and Optimal Dose Selection Drive Buy Rating for Acumen Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS), Aclaris Therapeutics (ACRS) and CryoPort (CYRX)
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Alector (ALEC)
Stifel Nicolaus Remains a Buy on Acumen Pharmaceuticals (ABOS)
UBS Adjusts Acumen Pharmaceuticals Price Target to $15 From $16, Maintains Buy Rating
H.C. Wainwright Sticks to Their Buy Rating for Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Acumen Pharmaceuticals (ABOS) and Cronos Group (CRON)
B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals (ABOS) Has a New Rating From Bank of America Securities
Analysts Are Bullish on Top Healthcare Stocks: Galera Therapeutics (GRTX), Acumen Pharmaceuticals (ABOS)
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
